167 related articles for article (PubMed ID: 11280763)
21. T cells are crucial for the anti-metastatic effect of anti-epidermal growth factor receptor antibodies.
Garrido G; Lorenzano P; Sánchez B; Beausoleil I; Alonso DF; Pérez R; Fernández LE
Cancer Immunol Immunother; 2007 Nov; 56(11):1701-10. PubMed ID: 17415565
[TBL] [Abstract][Full Text] [Related]
22. Elimination of CD4+ T cells in mice bearing an advanced sarcoma augments the antitumor action of interleukin-2.
Rakhmilevich AL; North RJ
Cancer Immunol Immunother; 1994 Feb; 38(2):107-12. PubMed ID: 7905789
[TBL] [Abstract][Full Text] [Related]
23. An extract of seeds from Aeginetia indica L., a parasitic plant, induces potent antigen-specific antitumor immunity in Meth A-bearing BALB/c mice.
Chai JG; Bando T; Kobashi S; Oka M; Nagasawa H; Nakai S; Maeda K; Himeno K; Sato M; Ohkubo S
Cancer Immunol Immunother; 1992; 35(3):181-5. PubMed ID: 1638554
[TBL] [Abstract][Full Text] [Related]
24. Activation of human lymphocytes by a monoclonal antibody to B lymphoblastoid cells; molecular mass and distribution of binding protein.
Hardy B; Galli M; Rivlin E; Goren L; Novogrodsky A
Cancer Immunol Immunother; 1995 Jun; 40(6):376-82. PubMed ID: 7627994
[TBL] [Abstract][Full Text] [Related]
25. CD5 blockade, a novel immune checkpoint inhibitor, enhances T cell anti-tumour immunity and delays tumour growth in mice harbouring poorly immunogenic 4T1 breast tumour homografts.
Alotaibi FM; Min WP; Koropatnick J
Front Immunol; 2024; 15():1256766. PubMed ID: 38487537
[TBL] [Abstract][Full Text] [Related]
26. M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation.
Xu C; Zhou X; Webb L; Yalavarthi S; Zheng W; Saha S; Schweickhardt R; Soloviev M; Jenkins MH; Brandstetter S; Belousova N; Alimzhanov M; Rabinovich B; Deshpande AM; Brewis N; Helming L
Cancer Immunol Res; 2024 Feb; 12(2):195-213. PubMed ID: 38091375
[TBL] [Abstract][Full Text] [Related]
27. A reservoir of stem-like CD8
Connolly KA; Kuchroo M; Venkat A; Khatun A; Wang J; William I; Hornick NI; Fitzgerald BL; Damo M; Kasmani MY; Cui C; Fagerberg E; Monroy I; Hutchins A; Cheung JF; Foster GG; Mariuzza DL; Nader M; Zhao H; Cui W; Krishnaswamy S; Joshi NS
Sci Immunol; 2021 Oct; 6(64):eabg7836. PubMed ID: 34597124
[TBL] [Abstract][Full Text] [Related]
28. Modulation of protective T cell immunity by complement inhibitor expression on tumor cells.
Varela JC; Imai M; Atkinson C; Ohta R; Rapisardo M; Tomlinson S
Cancer Res; 2008 Aug; 68(16):6734-42. PubMed ID: 18701498
[TBL] [Abstract][Full Text] [Related]
29. In Situ Sprayed Exosome-Cross-Linked Gel as Artificial Lymph Nodes for Postoperative Glioblastoma Immunotherapy.
Bao P; Gu HY; Jiang YC; Wang JW; Wu M; Yu A; Zhong Z; Zhang XZ
ACS Nano; 2024 May; 18(20):13266-13276. PubMed ID: 38709874
[TBL] [Abstract][Full Text] [Related]
30. CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects.
Glez-Vaz J; Azpilikueta A; Ochoa MC; Olivera I; Gomis G; Cirella A; Luri-Rey C; Álvarez M; Pérez-Gracia JL; Ciordia S; Eguren-Santamaria I; Alexandru R; Berraondo P; de Andrea C; Teijeira Á; Corrales F; Zapata JM; Melero I
Sci Adv; 2023 Aug; 9(33):eadf6692. PubMed ID: 37595047
[TBL] [Abstract][Full Text] [Related]
31. Antitumor effects of recombinant interleukin-6 expressed in eukaryotic cells.
Eisenthal A; Kashtan H; Rabau M; Ramakrishna V; Chaitchik S; Skornick Y
Cancer Immunol Immunother; 1993; 36(2):101-7. PubMed ID: 8425207
[TBL] [Abstract][Full Text] [Related]
32. Promotion of an Antitumor Immune Program by a Tumor-specific, Complement-activating Antibody.
Saxena R; Bushey RT; Campa MJ; Gottlin EB; Guo J; Patz EF; He YW
J Immunol; 2024 May; 212(10):1589-1601. PubMed ID: 38558134
[TBL] [Abstract][Full Text] [Related]
33. Experimental manipulations of afferent immune responses influence efferent immune responses to brain tumors.
Thomas DL; Kranz DM; Roy EJ
Cancer Immunol Immunother; 2008 Sep; 57(9):1323-33. PubMed ID: 18278494
[TBL] [Abstract][Full Text] [Related]
34. Facile generation of biepitopic antibodies with intrinsic agonism for activating tumor necrosis factor receptors.
Jhajj HS; Schardt JS; Khalasawi N; Yao EL; Lwo TS; Kwon NY; O'Meara RL; Desai AA; Tessier PM
Cell Chem Biol; 2024 May; 31(5):944-954.e5. PubMed ID: 38653243
[TBL] [Abstract][Full Text] [Related]
35. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors.
Melero I; Shuford WW; Newby SA; Aruffo A; Ledbetter JA; Hellström KE; Mittler RS; Chen L
Nat Med; 1997 Jun; 3(6):682-5. PubMed ID: 9176498
[TBL] [Abstract][Full Text] [Related]
36. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.
Chacon JA; Wu RC; Sukhumalchandra P; Molldrem JJ; Sarnaik A; Pilon-Thomas S; Weber J; Hwu P; Radvanyi L
PLoS One; 2013; 8(4):e60031. PubMed ID: 23560068
[TBL] [Abstract][Full Text] [Related]
37. Design Activity Framework for Visualization Design.
McKenna S; Mazur D; Agutter J; Meyer M
IEEE Trans Vis Comput Graph; 2014 Dec; 20(12):2191-200. PubMed ID: 26356933
[TBL] [Abstract][Full Text] [Related]
38. Use of in vitro human keratinocyte models to study the effect of cooling on chemotherapy drug-induced cytotoxicity.
Al-Tameemi W; Dunnill C; Hussain O; Komen MM; van den Hurk CJ; Collett A; Georgopoulos NT
Toxicol In Vitro; 2014 Dec; 28(8):1366-76. PubMed ID: 25091624
[TBL] [Abstract][Full Text] [Related]
39. The structure and immunomodulatory activity on intestinal epithelial cells of the EPSs isolated from Lactobacillus helveticus sp. Rosyjski and Lactobacillus acidophilus sp. 5e2.
Patten DA; Leivers S; Chadha MJ; Maqsood M; Humphreys PN; Laws AP; Collett A
Carbohydr Res; 2014 Jan; 384():119-27. PubMed ID: 24394883
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
